Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data
Επιτομή
Psoriatic arthritis (PsA) is a psoriasis (Ps)-associated inflammatory joint disease that affects peripheral joints, entheses, spine, and eyes. PsA and Ps are likely to be the same disease. PsA develops in nearly 70% of patients with Ps, and the hallmark of the disease is bone erosions and bone formation. Both innate and adaptive immunity appear to contribute to pathogenesis of PsA and Ps. Trauma may be a trigger factor for both PsA and Ps. The same T cell clones were reported to be present in both synovial tissues and skin lesions suggesting that a common antigen drives T cell immune response in the joints and skin lesions of patients with PsA. The IL-23/IL-17 axis plays a critical pathogenic role for both PsA and Ps, and biologics neutralizing IL-17A or IL-23/IL-12 are effective therapies for PsA and Ps. The differential expression of Th17 cytokines IL-17 and IL-22 at various sites could explain the different manifestations of the disease. IL-17 is highly expressed in peripheral joints and skin lesions and causes bone erosions. IL-22 is highly expressed in skin lesions and entheses, not peripheral joints, and cause bone formation. Finally, mannan from baker's yeast caused PsA-like arthritis and Ps-like skin lesions that were blocked by IL-17 treatment. These data suggest that PsA and Ps are likely to be the same disease exhibiting different manifestations depending on the local cytokine production. © 2016 Elsevier B.V.
Collections
Related items
Showing items related by title, author, creator and subject.
-
IL-1 cytokines in cardiovascular disease: Diagnostic, prognostic and therapeutic implications
Apostolakis, S.; Vogiatzi, K.; Krambovitis, E.; Spandidos, D. A. (2008)Interleukins (ILs) are key mediators in the chronic vascular inflammatory response underlying several aspects of cardiovascular disease. Due to their powerful pro-inflammatory potential, and the fact that they are highly ... -
Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
Vasileiadis G.K., Dardiotis E., Mavropoulos A., Tsouris Z., Tsimourtou V., Bogdanos D.P., Sakkas L.I., Hadjigeorgiou G.M. (2018)Current clinical experience with immunomodulatory agents and monoclonal antibodies in principle has established the benefit of depleting lymphocytic populations in relapsing–remitting multiple sclerosis (RRMS). B and T ... -
IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFNγ-producing T cells
Mavropoulos A., Varna A., Zafiriou E., Liaskos C., Alexiou I., Roussaki-Schulze A., Vlychou M., Katsiari C., Bogdanos D.P., Sakkas L.I. (2017)Our aim was to study CD19(+)CD27(+)CD24(high) memory and CD19(+)CD24(high)CD38(high) transitional and IL-10 + Breg cells, known to inhibit Th1 and Th17 cells in experimental arthritis, in psoriatic arthritis (PsA) and ...